The drug decitabine may offer an alternative for people with sickle cell disease who can’t tolerate current standard treatment with the drug hydroxyurea, says a study in the Dec. 1 issue of Blood.Hydroxyurea reactivates fetal hemoglobin, which is known to decrease complications caused by sickle cell disease. However, not all patients respond well to the medication.
